On September 25, 2026, Raymond James initiated coverage of Seaport Therapeutics (NASDAQGS:SPTX) with a “Strong Buy” recommendation. This follows a series of positive updates from other firms, including HC Wainwright & Co., which reiterated its “Buy” rating on September 10, and Jones Trading, which initiated coverage with a “Buy” rating on August 26.
As of September 1, 2026, out of 13 total analyst recommendations for Seaport Therapeutics, 5 were rated “Strong Buy,” 6 “Buy,” and 2 “Hold,” resulting in an 84.6% positive outlook. The current mean price target is $37.13, indicating a potential increase of 72.61% from the stock’s closing price of $21.51 on September 25. This marks a slight increase from the prior day’s close of $21.12.
Seaport Therapeutics reported an actual EPS of -0.73 on August 3, 2026, missing the estimated EPS of -0.6256, with quarterly revenue reported at $0.00, matching expectations.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
